5,887
Views
72
CrossRef citations to date
0
Altmetric
Review

LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential

, , , , &
Pages 821-833 | Received 20 Jan 2015, Accepted 09 Apr 2015, Published online: 28 May 2015

Figures & data

Figure 1. Downstream molecular events after addition of LB100 to chemotherapy and radiation. The schematic diagram summarizes the major downstream molecular events that occur after LB100 is administered concurrently with chemotherapy and/or radiation. Increased and decreased expression of the target proteins is indicated by a green and red arrow, respectively. The end consequences of LB100 treatment include increased tumor permeability to drug exposure, induction of cell differentiation, and tumor cell death resulting from mitotic catastrophe or apoptosis.

Figure 1. Downstream molecular events after addition of LB100 to chemotherapy and radiation. The schematic diagram summarizes the major downstream molecular events that occur after LB100 is administered concurrently with chemotherapy and/or radiation. Increased and decreased expression of the target proteins is indicated by a green and red arrow, respectively. The end consequences of LB100 treatment include increased tumor permeability to drug exposure, induction of cell differentiation, and tumor cell death resulting from mitotic catastrophe or apoptosis.

Table 1. Summary of pre-clinical studies utilizing LB100. Studies reflect a review of the literature as of November 2014

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.